STRO icon

Sutro Biopharma

0.8178 USD
+0.0317
4.03%
At close Jul 10, 4:00 PM EDT
After hours
0.7904
-0.0274
3.35%
1 day
4.03%
5 days
7.61%
1 month
-2.60%
3 months
42.97%
6 months
-55.79%
Year to date
-57.63%
1 year
-77.28%
5 years
-90.93%
10 years
-94.62%
 

About: Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.

Employees: 269

0
Funds holding %
of 7,312 funds
0
Analysts bullish %
of 3 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

30% more call options, than puts

Call options by funds: $35K | Put options by funds: $27K

25% more repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 32

0% more funds holding in top 10

Funds holding in top 10: 2 [Q4 2024] → 2 (+0) [Q1 2025]

3.87% less ownership

Funds ownership: 77.49% [Q4 2024] → 73.62% (-3.87%) [Q1 2025]

7% less funds holding

Funds holding: 123 [Q4 2024] → 114 (-9) [Q1 2025]

31% less first-time investments, than exits

New positions opened: 18 | Existing positions closed: 26

66% less capital invested

Capital invested by funds: $118M [Q4 2024] → $40.1M (-$77.4M) [Q1 2025]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$0.80
2%
downside
Avg. target
$1.60
96%
upside
High target
$2
145%
upside

3 analyst ratings

positive
33%
neutral
33%
negative
33%
Piper Sandler
Edward Tenthoff
145%upside
$2
Overweight
Upgraded
16 Jun 2025
B of A Securities
Tazeen Ahmad
2%downside
$0.80
Underperform
Maintained
19 May 2025
HC Wainwright & Co.
Andres Maldonado
145%upside
$2
Neutral
Reiterated
29 Apr 2025

Financial journalist opinion

Negative
Zacks Investment Research
2 months ago
Sutro Biopharma, Inc. (STRO) Reports Q1 Loss, Tops Revenue Estimates
Sutro Biopharma, Inc. (STRO) came out with a quarterly loss of $0.91 per share versus the Zacks Consensus Estimate of a loss of $0.63. This compares to loss of $0.95 per share a year ago.
Sutro Biopharma, Inc. (STRO) Reports Q1 Loss, Tops Revenue Estimates
Neutral
GlobeNewsWire
2 months ago
Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights
- Sharpened product candidate focus on its next-generation ADC portfolio, following strategic review and pipeline reprioritization -
Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights
Neutral
GlobeNewsWire
2 months ago
Sutro Biopharma to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that management will participate in two upcoming investor conferences.
Sutro Biopharma to Participate in Upcoming Investor Conferences
Neutral
GlobeNewsWire
2 months ago
Sutro Biopharma to Highlight its Next-Generation Exatecan and Dual-Payload ADC Programs in Presentations at AACR 2025
- Preclinical findings show STRO-004's promising anti-tumor activity and favorable safety profile - - Preclinical findings show STRO-004's promising anti-tumor activity and favorable safety profile -
Sutro Biopharma to Highlight its Next-Generation Exatecan and Dual-Payload ADC Programs in Presentations at AACR 2025
Neutral
GlobeNewsWire
3 months ago
Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025
- The late-breaking oral presentation at SGO 2025 highlights consistent response rates observed in patients across all levels of FRα expression of 25% or greater - - The late-breaking oral presentation at SGO 2025 highlights consistent response rates observed in patients across all levels of FRα expression of 25% or greater -
Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025
Negative
Benzinga
3 months ago
Penny Stock Sutro Biopharma Cuts Costs, Refocuses Pipeline
On Thursday, Sutro Biopharma, Inc. STRO prioritized its antibody-drug conjugates (ADC) pipeline, including three wholly-owned preclinical programs in its next-generation ADC pipeline.
Penny Stock Sutro Biopharma Cuts Costs, Refocuses Pipeline
Negative
Zacks Investment Research
3 months ago
Sutro Biopharma, Inc. (STRO) Reports Q4 Loss, Tops Revenue Estimates
Sutro Biopharma, Inc. (STRO) came out with a quarterly loss of $0.89 per share versus the Zacks Consensus Estimate of a loss of $0.86. This compares to earnings of $0.42 per share a year ago.
Sutro Biopharma, Inc. (STRO) Reports Q4 Loss, Tops Revenue Estimates
Neutral
GlobeNewsWire
3 months ago
Sutro Biopharma Reports Full Year 2024 Financial Results and Business Highlights
– Sutro announced a strategic portfolio review resulting in prioritization of wholly-owned next-generation ADC programs; Key management changes announced as part of transition –
Sutro Biopharma Reports Full Year 2024 Financial Results and Business Highlights
Neutral
GlobeNewsWire
3 months ago
Sutro Biopharma Announces Strategic Portfolio Review Resulting in the Prioritization of its Next-Generation ADC Pipeline
– Sutro will rapidly advance next-generation exatecan and dual-payload ADC programs; luveltamab tazevibulin development to be deprioritized as Sutro continues to seek a partner –
Sutro Biopharma Announces Strategic Portfolio Review Resulting in the Prioritization of its Next-Generation ADC Pipeline
Neutral
GlobeNewsWire
4 months ago
Sutro Biopharma to Present at the TD Cowen 45th Annual Health Care Conference
SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that management will present at the TD Cowen 45th Annual Health Care Conference taking place March 3-5, 2025 in Boston, MA.
Sutro Biopharma to Present at the TD Cowen 45th Annual Health Care Conference
Charts implemented using Lightweight Charts™